Industry Archives - Australian Pharmacist

For pharmacists, this presents an obligation to critically assess the evidence of benefit, weigh potential risks and interactions and apply rigorous professional standards when dispensing.

What’s the leading indication for medicinal cannabis prescribing?

Chronic non-cancer pain. But the quality of supporting evidence is far less robust than the demand for treatment suggests. Evidence shows that medicinal cannabis may provide a small benefit for a subset of patients who live with chronic pain, said Professor Suzanne Nielsen MPS, Deputy Director of the Monash Addiction Research Centre in Melbourne. [caption id="attachment_10405" align="alignright" width="318"] naloxone

Professor Suzanne Nielsen MPS[/caption] ‘And of those people who find it efficacious, the benefits are often quite small,’ she said. Concerns also remain about the safety of long-term use. ‘We already know that the pattern we saw with opioid [dependence] has been replicated with medicinal cannabis, with recent studies showing around one in four people using medicinal cannabis meets criteria for cannabis dependence,’ Prof Nielsen said. Alongside evidence-based pharmacological approaches, some of the most effective treatments for chronic pain is typically multidisciplinary care, including behavioural and physical therapies. ‘This helps to avoid some of the serious [adverse] effects we see with some medicines,’ she said. Some studies show that medicinal cannabis is beneficial for patients with comorbid conditions, such as chronic pain and depression, Prof Nielsen said. But when patients are assessed for therapeutic interventions for these conditions, it’s integral that healthcare professionals who are familiar with the whole person’s care are involved. ‘Someone with comorbidities alongside their chronic pain is likely to be on multiple medications where there's risk of interactions,’ Prof Nielsen said. ‘Ideally, this should be assessed and managed by a GP, perhaps with specialist input – and less ideally by a cannabis clinic that's not necessarily managing the rest of a patient's care.’

Does the evidence support medicinal cannabis for anxiety?

Not at this point, Prof Nielsen said. ‘While the evidence signals there's a possible effect for cannabidiol (CBD), the studies we're looking at often have really important limitations,’ she said. ‘They're often very small, might only have a one-off dose of CBD, and may be looking at experimentally-induced stress – not necessarily treatment of an anxiety condition.’ And for some patients, tetrahydrocannabinol (THC) containing medicines can worsen symptoms of anxiety. ‘We've seen reports of acute psychosis, particularly when people are using higher concentration THC products,’ she said. ‘So there are a number of factors we need to consider, particularly for individuals who might be predisposed to those risk factors.’ There is a range of both psychological and pharmacological treatments available to treat anxiety, including cognitive behavioural therapy and antidepressants, such as selective serotonin reuptake inhibitors. ‘It's really about remembering the therapeutic hierarchy and going with the first-line medicines, which are safest to try first before unapproved, experimental medications,’ Prof Nielsen said.

Can cannabis improve sleep or worsen insomnia?

Sleep disturbances such as insomnia are another frequent driver of medicinal cannabis prescribing. Yet, here too, the evidence base is ‘mixed’, Prof Nielsen said. ‘There are often significant weaknesses in study designs, and medicinal cannabis is often not compared against the most effective treatment,’ she said. THC can induce drowsiness and create a perception of improved sleep among people taking it for insomnia. ‘But actually, when we look at objective measures of sleep for people, there's often nothing that's statistically or clinically different to placebo,’ Prof Nielsen said. Furthermore, tolerance can develop with ongoing use, and cessation may trigger rebound insomnia. ‘People who have tried medicinal cannabis and then have stopped using it often find their sleep is much worse,’ she said. ‘And there is that risk of the person developing cannabis use disorder and dependence as well.’

Is medicinal cannabis the first-line therapy for any conditions?

No. There are more than 1,000 medicinal cannabis products, and most are unregistered and have not undergone safety, quality or efficacy assessment by the TGA, said Myfanwy Graham, NHMRC Postgraduate Scholar, Monash University, Fulbright Alumna in Public Health Policy, and appointed member of the TGA’s Medicinal Cannabis Expert Working Group.* [caption id="attachment_30412" align="aligncenter" width="400"]

Myfanwy Graham[/caption] ‘TGA guidance on medicinal cannabis states that it is not a first-line treatment strategy and standard, registered treatments should be trialled or deemed inappropriate before consideration of medicinal cannabis on a case-by-case basis,’ she said. When standard treatments prove ineffective in patients with conditions such as multiple sclerosis or rare forms of epilepsy – there is ‘good evidence’ to support the use of medicinal cannabis as an appropriate option, Prof Nielsen said. ‘And we have TGA-approved products for those conditions too.’ ‘[These are] Sativex (nabiximols; Schedule 8) and Epidyolex (CBD; Schedule 4),’ Ms Graham added.

What are the potential risks and adverse effects?

Patients who are interested in trying these medicines should be made aware of the risks, including the potential for dependence, so they can make an informed decision, Prof Nielsen said. This includes informing patients about potential adverse effects of medicinal cannabis, including:

sedation and drowsiness
confusion
tachycardia
dry mouth
anxiety, nausea and vomiting
appetite changes.

‘Older patients may be more susceptible to adverse effects and there are neurocognitive considerations with the use of THC-containing medicinal cannabis products in individuals under 25 years of age,’ Ms Graham said. When dispensing ongoing prescriptions of medicinal cannabis, pharmacists should also check in with patients about the effectiveness of therapy and if they are experiencing any adverse effects. This approach is similar to the ongoing risk assessment applied to patients on long-term opioid therapy. ‘There should be an ongoing conversation around whether people are developing signs of cannabis use disorder, having difficulty controlling the amount they use, or if they tend to use it to address other symptoms as well,’ Prof Nielsen said. ‘If they are experiencing cravings and spending a lot of time thinking about using medicinal cannabis, this is suggestive that there should be an assessment of developing cannabis use disorder.’ Next steps include having a discussion with the prescriber. ‘There are drug and alcohol clinical advisory service hotline numbers in every state that they can call as well,’ she said.

Are there any contraindications and interactions to be aware of?

Pharmacists play an important role in terms of screening and counselling patients on medicinal cannabis use before dispensing, Ms Graham said. This includes looking out for contraindications such as:

people with a current or past psychotic disorder, or an active mood or anxiety disorder
women who are pregnant, planning to become pregnant or breastfeeding
people with unstable cardiovascular disease.

‘There are also cannabinoid-specific considerations such as liver function, and driving and occupational considerations,’ she said. There are also a host of interactions between cannabidiol and other medicines, including:

warfarin
tacrolimus
valproate
methadone
lithium.

What are pharmacists’ professional obligations?

The Australian Health Practitioner Regulation Agency (Ahpra) recently released guidance on professional responsibilities with medicinal cannabis, said Ms Graham. ‘The first port of call for pharmacists is being really well informed about the current state of evidence and regulations, both at a state and federal level, and being able to engage with patients about any questions they have [around] medicinal cannabis,’ she said. While the dose titration of medicinal cannabis used is product and condition specific, Ms Graham said the general rule of thumb is to ‘start low and go slow’. ‘Pharmacists should have an awareness of maximum daily doses of THC, patients’ overall THC intake if they have a number of different prescriptions dispensed, and [any] dose escalation over time,’ she said. ‘And ensure that supply is in line with therapeutically appropriate quantities.’ As most medicinal cannabis approvals are for Schedule 8 products, pharmacists must complete Schedule 8 prescriber verification processes before dispensing medicinal cannabis, along with checking TGA prescription approvals. ‘[This must be done] in line with what’s required in their state or territory,’ Ms Graham added. *Myfanwy Graham’s contributions do not represent the views of the TGA or the Medicinal Cannabis Expert Working Group

The hidden toll of ‘good enough’ asthma control

Industry Chloe Hava - September 3, 2025

Parents have reported persistent anxiety about asthma attacks. Pharmacists can help to pivot care from treating flare-ups to stopping them.

Read

Ethical lessons for Australian pharmacists from overseas

Industry Peter Guthrey FPS - September 3, 2025

What ethical lessons do Australian pharmacists need to heed from other countries? A panel of experts at the FIP Congress filled in the blanks.

Read

As medicinal cannabis prescriptions climb, does the evidence hold up?

Industry Chloe Hava - September 1, 2025

Medicinal cannabis prescribing in Australia has risen sharply in recent years, with the TGA recording thousands of approvals each month.

Read

FIP: ‘Embrace new opportunities’

Industry Peter Guthrey FPS - September 1, 2025

The International Pharmaceutical Federation (FIP) Congress opened overnight in Copenhagen, honouring some of the world’s leading pharmacists.

Read

Common analgesics may be contributing to antimicrobial resistance

Industry Chloe Hava - August 27, 2025

New research has found that ibuprofen and paracetamol may contribute to antimicrobial resistance – particularly when used in combination.

Read

Overdose deaths hit decade-high in Victoria

Industry Chloe Hava - August 25, 2025

A recent report conducted by the Coroners Court of Victoria found that overdose deaths in 2024 were the highest they have been in a decade. And of the 584 Victorians who died of an overdose last year, a stark proportion...

Read

Ozempic now indicated to prevent CKD progression

Industry Chloe Hava - August 20, 2025

Ozempic is the first medicine in Australia approved to slow kidney disease progression in patients with both type 2 diabetes and CKD.

Read

New burns care tool for pharmacists

Industry Chloe Hava - August 18, 2025

New national burns resource supports frontline assessment, management and prompt referral of burn injuries.

Read

The mindset shift that’s key to prescribing success

Industry Chloe Hava - August 13, 2025

Pharmacist prescribing is emerging as a powerful extension of primary care, with potential to improve access and enhance patient outcomes.

Read

New ATAGI advice to prevent RSV vaccination errors

Industry Chloe Hava - August 11, 2025

The Australian Technical Advisory Group on Immunisation (ATAGI) has made an unusual move by issuing a statement on RSV vaccination errors.

Read

12 3...101 Page 1 of 101

Shifting the perspective from reactive to proactive

Identifying undiagnosed or uncontrolled asthma

Picking up on poor inhaler technique

Improving adherence and long-term management

UK: Put in place structures to navigate undue pressure

Basic ethical principles ‘more important’ when prescribing

What’s the leading indication for medicinal cannabis prescribing?

Does the evidence support medicinal cannabis for anxiety?

Can cannabis improve sleep or worsen insomnia?

Is medicinal cannabis the first-line therapy for any conditions?

What are the potential risks and adverse effects?

Are there any contraindications and interactions to be aware of?

What are pharmacists’ professional obligations?

‘Embrace new opportunities’

Professor Lisa Nissen FPS, new FIP Fellow

How do paracetamol and ibuprofen increase antimicrobial resistance?

Are there certain populations who could be more at risk?

What advice should pharmacists provide to patients?

Shifting the perspective from reactive to proactive

Identifying undiagnosed or uncontrolled asthma

Picking up on poor inhaler technique

Improving adherence and long-term management

UK: Put in place structures to navigate undue pressure

Basic ethical principles ‘more important’ when prescribing

What’s the leading indication for medicinal cannabis prescribing?

Does the evidence support medicinal cannabis for anxiety?

Can cannabis improve sleep or worsen insomnia?

Is medicinal cannabis the first-line therapy for any conditions?

What are the potential risks and adverse effects?

Are there any contraindications and interactions to be aware of?

What are pharmacists’ professional obligations?

‘Embrace new opportunities’

Professor Lisa Nissen FPS, new FIP Fellow

How do paracetamol and ibuprofen increase antimicrobial resistance?

Are there certain populations who could be more at risk?

What advice should pharmacists provide to patients?

Shifting the perspective from reactive to proactive

Identifying undiagnosed or uncontrolled asthma

Picking up on poor inhaler technique

Improving adherence and long-term management

UK: Put in place structures to navigate undue pressure

Basic ethical principles ‘more important’ when prescribing

What’s the leading indication for medicinal cannabis prescribing?

Does the evidence support medicinal cannabis for anxiety?

Can cannabis improve sleep or worsen insomnia?

Is medicinal cannabis the first-line therapy for any conditions?

What are the potential risks and adverse effects?

Are there any contraindications and interactions to be aware of?

What are pharmacists’ professional obligations?

‘Embrace new opportunities’

Professor Lisa Nissen FPS, new FIP Fellow

How do paracetamol and ibuprofen increase antimicrobial resistance?

Are there certain populations who could be more at risk?

What advice should pharmacists provide to patients?

Shifting the perspective from reactive to proactive

Identifying undiagnosed or uncontrolled asthma

Picking up on poor inhaler technique

Improving adherence and long-term management

UK: Put in place structures to navigate undue pressure

Basic ethical principles ‘more important’ when prescribing

What’s the leading indication for medicinal cannabis prescribing?

Does the evidence support medicinal cannabis for anxiety?

Can cannabis improve sleep or worsen insomnia?

Is medicinal cannabis the first-line therapy for any conditions?

What are the potential risks and adverse effects?

Are there any contraindications and interactions to be aware of?

What are pharmacists’ professional obligations?

‘Embrace new opportunities’

Professor Lisa Nissen FPS, new FIP Fellow

How do paracetamol and ibuprofen increase antimicrobial resistance?

Are there certain populations who could be more at risk?

What advice should pharmacists provide to patients?

Subscribe to our newsletter

Subscribe to our newsletter

CONTACT

FOLLOW US